Cutler Group LP Arrowhead Pharmaceuticals, Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Cutler Group LP holds 2,500 shares of ARWR stock, worth $46,849. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,500

Previous 2,500 -0.0%

Holding current value

$46,849

Previous $14,000 50.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$29.63 - $48.31 $1,096 - $1,787	37 Added 4.63%	837 $27,000
Q2 2022 Aug 04, 2022	BUY	$27.79 - $50.61 $22,232 - $40,488	800 New	800 $28,000
Q1 2022 Apr 14, 2022	SELL	$39.62 - $69.97 $63,391 - $111,952	-1,600 Closed	0 $0
Q1 2021 Apr 26, 2021	SELL	$61.35 - $90.47 $257,670 - $379,974	-4,200 Reduced 72.41%	1,600 $106,000
Q4 2020 Jan 21, 2021	BUY	$43.82 - $85.37 $78,876 - $153,666	1,800 Added 45.0%	5,800 $445,000
Q3 2020 Oct 27, 2020	BUY	$33.21 - $51.27 $33,210 - $51,270	1,000 Added 33.33%	4,000 $172,000
Q2 2020 Jul 22, 2020	BUY	$26.12 - $43.27 $10,448 - $17,308	400 Added 15.38%	3,000 $129,000
Q1 2020 May 07, 2020	BUY	$20.56 - $63.12 $47,123 - $144,671	2,292 Added 744.16%	2,600 $74,000
Q4 2019 Feb 06, 2020	BUY	$28.14 - $73.01 $8,667 - $22,487	308 New	308 $19,000
Q1 2018 May 11, 2018	SELL	$3.72 - $7.64 $3,385 - $6,952	-910 Closed	0 $0
Q4 2017 Jan 17, 2018	SELL	$3.14 - $4.5 $314 - $450	-100 Reduced 9.9%	910 $3,000
Q3 2017 Oct 17, 2017	BUY	$1.69 - $4.33 $1,706 - $4,373	1,010	1,010 $4,000

Others Institutions Holding ARWR

# of Institutions

293

Shares Held

90.6M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.98B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account